ZURICH (Reuters) – Roche said on Thursday that the U.S. Food and Drug Administration had approved a treatment using its drugs Venclexta plus Gazyva for people with previously untreated chronic lymphocytic leukemia.

“Venclexta plus Gazyva is the only chemotherapy-free option of fixed duration that provides durable responses to help people live longer without progression of their disease, compared to a standard-of-care,” Roche’s Chief Medical Officer Sandra Horning said in a statement.

 

Reporting by Brenna Hughes Neghaiwi; Editing by Michelle Martin

 

Reuters source:

https://www.reuters.com/article/us-roche-hldg-venclexta/roche-fda-approves-drug-combo-venclexta-plus-gazyva-for-previously-untreated-chronic-lymphocytic-leukemia-idUSKCN1SM0EG